This SMURF2-mediated degradation mechanism bypasses the traditional VHL (von Hippel-Lindau) pathway, offering an alternative strategy to control HIF1α levels in cancers where VHL is mutated, such as in renal cell carcinoma (23). The gene discussed is SMURF2; the disease is cancer.